EU regulators reverse course, approve Alzheimer’s drug Leqembi
HQ Team November 19, 2024: The European Medicines Agency (EMA) granted conditional approval for lecanemab, for the treatment of early Alzheimer’s disease in
HQ Team November 19, 2024: The European Medicines Agency (EMA) granted conditional approval for lecanemab, for the treatment of early Alzheimer’s disease in
HQ Team November 19, 2024: Eli Lilly announced promising results from its Phase 2 clinical trial of muvalaplin, an oral medication designed to
Climate inaction may cost the global economy $190 trillion by 2070 due to a decline in agricultural and labour productivity and damage to capital and
HQ Team November 16, 2024: Shingles vaccination has proven effective in preventing herpes zoster and its related complications. Recent research suggests that the
Measles cases worldwide have risen 20% year-on-year in 2023 to about 10.3 million due to inadequate access to vaccines, according to new estimates
HQ Team November 15, 2024:Allergies are a source of great social and physical impairment for people suffering from them. Treatments are long-drawn, expensive
HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for
HQ Team November 14, 2024: Recent research published in Brain Medicine found air pollution as a significant environmental risk factor for Autism Spectrum Disorder
HQ team November 14, 2024: The 29th Conference of the Parties (COP29) to the United Nations Framework Convention on Climate Change (UNFCCC), held